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Multiple Sclerosis (MS) presents in a variety of clinical forms associated with a diverse grade of
neurological impairment, different prognosis and, possibly, multiple pathogenic mechanisms. Thus,
whereas relapsing-remitting (RR) MS appears to be largely driven by inflammatory processes,
neurodegeneration, partially independent from inflammation, drives primary progressive (PP) and
secondary progressive (SP) MS. An extensive analysis of neuroinflammation in the different forms of
MS was performed by evaluating immunophenotypic and functional parameters in MBP-stimulated
T lymphocytes of 103 MS patients (26 benign (BE) MS, 30 RRMS, 33 SPMS and 14 PPMS) and 40
healthy controls (HC). Results showed that: i) IL-17-producing and RORC/yt-expressing CD4+ T cells
(THI7 lymphocytes), as well as IL-6 expressing CDI4+ cell were augmented in all patients; ii) IL-22-
expressing cells were increased in all forms of MS with the exception of PPMS; iii) TGF-p-expressing
B cells were increased only in RRMS; and iv) GATA3-, NFATc-l, IL-13-, and IL-25-expressing cells
(TH2 lymphocytes) were augmented in RRMS and BEMS patients alone. Data herein indicate a pivotal
pathogenic role of THl7-driven inflammation in all clinical forms of MS and suggest that control over
disease (RRMS and BEMS) is associated not with lack of inflammation per se, but rather with the
activation of immune-mediated anti-inflammatory mechanisms. These results could help the design of
novel diagnostic and therapeutic approaches.
Multiple sclerosis (MS), a demyelinating
autoimmune disease ofthe central nervous system, is
triggered by molecular mimicry with cross-reacting
and yet undefined epitopes and is associated with the
activation of CD4+ TH I and THI7 lymphocytes,
CD8+ T lymphocytes, and B lymphocytes, as well as
myeloid dendritic cells. The activation of these cells
drives the neuroinflammation that plays an important
role in damaging the myelin sheath (I, 2).
The most common clinical phenotype ofMS is the
relapsing-remitting (RR) form, which is characterized
by an acute onset of symptoms and signs suggestive
of neurological dysfunction, followed by complete
or partial recovery. The long-term prognosis of
RRMS is usually unfavorable, since patients enter
the so-called secondary progressive (SP) phase of
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the disease and accumulate irreversible neurological
disability. A different pattern, primary progressive
(PP) MS, is seen in patients showing a progressive
course from the onset; an even rarer form of disease
is benign MS (BEMS): in this case absent or minimal
neurological impairment is seen years after the onset
manifestation. Notably, whereas RRMS appears
to be largely driven by inflammatory processes,
neurodegeneration plays an important role in the
chronic brain and spinal cord injury in patients with
PP and SPMS.
Proinflammatory cytokines have long been
suspected to play a role in the induction and
pathogenesis of MS (3-5). The recent clarification of
the factors involved in the differentiation pathways
of antigen-stimulated CD4+ T cells has prompted
the need to investigate such pathways in details.
To summarize, firstly the TH I lineage is promoted
by IL-12 and requires the T-bet transcription factor
(TF). TH2 produce IL-25: this protein inhibits the
development ofTH 17 cells directly, secondarily to its
boosting effect on IL-13 (6-8) -a TH2 cytokine with
a suppressive ability on TH 17 cells-, or via its effect
on NFATc-l, thus promoting Th2 cell differentiation
through GATA-3 expression in an IL-4-dependent
manner (9). TH 17 differentiation requires multiple
cytokines including IL-6, TGF-~, IL-21, and IL-23,
and is dependent on the RORCly! TF; in tum TH 17
cells produce IL-17, IL-21 and IL-22 (10) and play
an important role in inflammation and autoimmune
diseases (II). Finally, TH91ymphocytes differentiate
in the presence oflL-4 and TGF-~, and produce IL-9
(12, 13).
TH 17 lymphocytes were shown to be involved
in the pathogenesis of MS (14, 15). Thus, IL-
17 concentration is higher in MS patients with
active disease in comparison to healthy subjects or
individuals with quiescent disease (16, 17); IL-17
expression correlates with MS severity (18); high
levels of IL-17 are present in both plaques and CSF
of MS patients (17-19); IL-17 production correlates
with the number of active plaques detected by MRI
(17, 18); IL-17 generation by CNS-infiltrating T
cells and glial cells is associated with phases of
disease activity (17). Notably, IL-22 and IL-17, two
of the cytokines produced by TH I7 cells, cooperate
in disrupting the blood-brain barrier (BBB) integrity
by breaking tight junctions. Thus, BBB endothelial
cells express IL-17R and IL-22R; cytokines binding
to their receptors disrupt cellular gap junctions
leading to an increased permeability that facilitates
cell migration through the BBB (20).
The role of TH9 in this disease is less clear,
even if IL-9 neutralization by monoclonal antibody
delays the onset of EAE (experimental autoimmune
encephalomyelitis), an animal model of MS.
Moreover, the observation that IL-9R-deficient mice
develop a milder form of EAE with reduced levels
of TH 17 cells and IL-6-producing macrophages
reinforces the possible pathogenic role of IL-9 in MS
(21). Finally, it was shown that IL-9 in combination
with TGF-~ can promote TH 17 cell differentiation,
and, on the other hand, that TH 17 cells can produce
IL-9 (22).
To clarify the association of different Th
lymphocyte subsets with the pathogenesis of MS
and the different disease patterns observed in this
disease, we stimulated peripheral immune cells of
PP, SP, RR, and BEMS patients and healthy controls
(HC) with a pool of myelin basic protein (MBP)-
antigenic peptides and examined cytokine and
TF profiles. Results suggest that TH2 activation -
possibly with the contribution of TGF~-secretingB
lymphocytes - draws the difference between clinical
activity and lack thereof.
MATERIALS AND METHODS
Patients and controls
One-hundred-three patients with Multiple Sclerosis
as diagnosed by clinical and laboratory parameters and
followed by the Centro Sclerosi Multipla, Don Gnocchi
Foundation in Milano, Italy were included in the study.
Thirty RRMS patients (median age= 40 years; range=
20-59 years; 19 females and II males) were classified
as being affected by stable MS (SMS). The diagnosis of
SMS was confirmed by brain and spinal cord magnetic
resonance imaging (MRI) with gadolinium: MRI showed
no areas of enhancement at the time of enrolment.
Median disease duration was 7 years (range: 1-29 years);
the median Kurtze Expanded Disability Status Scale
(EDSS) score was 1,5 (range: 1-6). Fourteen patients
(median age= 50 years; range= 37-64 years; 6 females
and 8 males) has a diagnosis of PPMS as confirmed by
the typical progressive clinical course and by brain and
spinal cord MRI with gadolinium that showed a particular
involvement of spinal cord with many lesions but no
enhancement at the time of enrolment. Median disease
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duration was 12 years (range: 3-15 years); the median
EDSS was 6 (range: 4-7). Thirty-tree patients (median
age= 49 years; range = 32-67 years; 21 females and 12
males) were diagnosed as being affected by SPMS on
the basis of the clinical history and of brain and spinal
cord MRI with gadolinium that evidenced a stability of
the lesion load at the time of enrolment. Median disease
duration was 20 years (range: 6-35 years); the median
EDSS was 6,5 (range: 4,5-8). Finally, 26 patients (median
age= 45 years; range= 36-61 years; 18 females and 8
males) were affected by BEMS as confirmed by brain and
spinal cord MRI with gadolinium: MRI showed stability
or in many cases an improvement of the lesion load at the
time of enrolment. BEMS was determined to be present
based on the most widely accepted definition, i.e. an
Expanded Disability Status Scale (EDSS) score of 3.0 or
less (meaning that the patient is fully ambulatory, but may
have moderate disability in one functional system or mild
disability in up to four functional systems), after 15 years
or more from the clinical onset of disease
Median disease duration was 21 years (range: 15-30
years); the median Kurtze Expanded Disability Status
Scale (EDSS) score was 2 (range: 0-3). None of the
patients had received immunosuppressive drugs in the
year prior to the study period; all of them gave informed
consent according to a protocol approved by the local
ethics committee of the Don Gnocchi Foundation. Finally
a group of 40 sex- and age-matched healthy controls (HC)
(median age= 48 years; range 33-62; 27 females and 13
males) were enrolled as well in the study.
Blood sample collection and cell separation
Thirty milliliters of whole blood was collected in
vacutainer tubes containing ethylenediaminetetraacetic
acid (EDTA) (Becton Dickinson & Co., Rutherford, NJ,
USA). PBMC were separated on lymphocyte separation
medium (Organon Teknika Corp., Durham, NC, USA) and
washed twice in PBS. Viable leukocytes were determined
using a Scepter" Handheld Automated Cell Counter
(Millipore, MA, USA).
Synthesis ofthe MBP peptides
Thirty-one HLA I restricted and 7 HLA II restricted
promiscuous peptides partially overlapping and spanning
the whole MBP were used to evaluate MBP-specific
responses; two 9 mer MBP peptides and one 15 mer MBP
peptide with the lowest score were used, respectively as
negative controls for HLA I and HLA II MBP restricted
responses. All these peptides have been previously used to
asses MBP- specific immune responses (23). To reassess
the optimal doses needed to stimulate cells, preliminary
experiments were performed with PBMC from 5 patients
with stable disease and from 5 healthy controls. CFSE
proliferation assay in the absence of stimulation or in
the presence of different doses (10, 50 and 100 ug/ml) of
either the MBP peptide pools or the peptide control pool
confirmed that proliferation of CD4+ and CD8+ T cells
could be detected upon stimulation with the antigenic
MBP peptides alone, indicating that data herein are
indeed relative to antigen-specific T-cell clones. Peptides
were synthesized using Fmoc chemistry; their purity, as
assayed by HPLC, was >70% and their composition was
verified by mass spectrometry. Lyophilized peptides were
dissolved at 25mg/ml in DMSO or sterile water to prepare
peptide pools (LOug/ml final concentration) (23).
Stimulation ofPBMCfor FACS analysis
One million PBMC were stimulated with non-
immunogenic peptides or with a pool of antigenic
MBP peptides (23) (10 ug/rnl) + anti-CD28 mAb (clone
37407.111; R&D Systems)(l ug/ m!) to facilitate co-
stimulation, at 37°C in a humidified 5% C02 atmosphere
for 24 h. For cytokine analyses, 10 ug/ml Brefeldin A
(Sigma-Aldrich, St. Louis, MO,USA) was added to the
cell cultures during the last 6 h of stimulation to block
protein secretion.
Immunofluorescent staining
PBMC were stained with anti-CD3, -CD4, -CD 19 and
-CD 14 monoclonal-antibodies (mAbs) (Beckman Coulter,
Brea, CA, USA) for 30 min at 4°C in the dark, washed
in PBS, and treated with FIX and PERM (FIX & PERM
Cell Permeabilization kits; eBioscience San Diego, CA,
USA), and incubated for 30 min at 4°C in the dark with
mAbs against the following proteins: RORC/ yr, T-bet,
GATA3, NFkB, NFATcl, IFN-y, IL-4, IL-6, IL-9, IL-IO,
IL-12p35, IL-13, IL-17a, IL-21, IL-22, IL-23p40, IL-
25 and TGF-~; mAbs were Fluorescein Isothiocyanate
(FITC) or Phycoerythrin( PE)-conjugated.
Monoclonal Abs
The following mAbs were used: Phycoerythrin-
Cyanin-5 (PC-5) labeled anti-CD3 (clone UCHTl)
(mouseIgG I) and Phycoerythrin-Cyanin-7 (PC-7)-
labeled anti-CD4 (clone SFCIl2T40 II) (mouse IgG I),
or anti-CD 19- PC-5 (clone J4.119) (mouse IgG I) -or anti-
CDl4- PC-5(clone 116), (Beckman-Coulter, Fullerton,
CA, USA). The intracellular molecule detection mAbs
used were: anti-human IL-IO- PE (clone JES9D7; mouse
IgG I isotype; Caltag Laboratories), anti-human IL-4-
FITC (clone MP4-25D2, rat IgGl k isotope, eBioscience
Cornerstone Court West, San Diego, CA, USA), anti-
human TGF-~- PE (clone 9016, mouse IgGI isotype R&D
Systems), anti-human IFNy-PE, anti-human IL-6- FITC
(clone 1936, mouse IgG2B isotope, R&D Systems), anti-
human IL-9- PE (clone MH9A4, mouse IgG2B.k isotype,
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Biolegend, San Diego, CA, USA), anti-human IL-12-
FITC (clone 27537, mouse IgG] isotype, R&D), anti-
human IL-13- FITC (clone 32007, mouse IgGlisotype,
R&D), anti-human IL-17a-FITC (clone BLl68, mouse
IgG], isotypc, Biolcgend), anti-human IL-21-PE (clone
3A3-N2, mouse IgG] isotype, eBioseienee), anti-human
IL-22-PE (clone 142928, mouse IgG] isotype R&D),
anti-human IL-23-PE (clone C 11.5, mouse IgG], isotype,
Biolegend), anti-human IL-25-PE (IL-17E, clone 182203,
mouse IgG Iisotype, R&D), anti-mouse/human RORC/
yr-PE (clone AFKJS-9 , rat IgGca isotype, eBioscience),
anti-mouse/human T-bet- PE (clone 39D, mouse IgG]
isotype, eBioscience), anti-mouse/human GATA3-PE
(clone TWAY, rat IgGc]U isotype, eBioscience), anti-
human NFkB-FITC (clone C-5 , mouse IgGca isotype,
Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-
human NFATcl-PE (clone H-IO, mouse IgG] isotype,
Santa Cruz Biotechnology).
Cvtometric analvsis
Analyses were performed using a Beckman-Coulter
Cytomics FC-500 flow cytometer equipped with a
single 15 mW argon ion laser operating at 488 nm and
interfaced with CXP Software 2.1. Two-hundred thousand
events,( median T cells = 110.000; median B cells=
20.000; median monocytes :70.000) were acquired
and gated on Forward and Side scatter properties for
lymphocyte or monocyte and on CD3+ for CD4+ T cells,
considering isotype background. Green florescence from
FITC (FL I) was collected through a 525-nm band-pass
filter, orange-red fluorescence from PE (FL2) through
a 575-nm band-pass filter, deep-red fluorescence from
PC-5 (FL4) through a 670-nm band-pass filter, and blue
fluorescence from PC-7 (FL5) through a nO-nm band-
pass filters. Data were collected using linear amplifiers
for forward and side scatter and logarithmic amplifiers
for FL I, FL2, FL4 and FL5. Samples were first run
using isotype control or single fluorochrome-stained
preparations for color compensation. Rainbow Calibration
Particles (Spherotec, Inc. Lake Forest, IL, USA) were
used to standardize results.
Luminex fluorescent head human and ELISA cytokine
immunoassays
Two million PBMC were incubated on 24-well
plates in I ml of RPMI 1640 medium (containing 10%
human serum and 2 mmol/L glutamine and penicillin/
streptomycin) in the presence of non-immunogenic
peptides or of a pool of antigenic MBP peptides (10 J.lg/
ml) (Saresella et al., 2008) at 37°C in a humidified 5%
C02 atmosphere for 5 days in 24 well plates. Supernatants
were collected for detection of cytokines.
Cytokine concentrations by multiplex immunoassay and
ELISA immunoassay
Cytokines were determined using multiplex sandwich
immunoassays with the Fluorokine Multi Analyte
Profiling Kit (R&D Systems, Minneapolis, MN, USA)
according to the manufacturer's protocol; the following
eytokines were included in the kit: IL-17a, IL-6, IL-IO
and IFNy. Interleukin-12p70, IL-21, IL-22, IL-23, TGFp,
and IL-9 were measured by commercially available
ELISA kits (Quantikine Immunoassay R&D Systems).
The concentration of cytokines was calculated using
a standard curve derived from the reference cytokine
concentration standards supplied by the manufacturer.
Statistical analysis
Quantitative data were not normally distributed
(Shapiro-Wilk test) and are thus summarized as median
and interquartile Range (IQR; 25 and 75 percentiles).
Comparisons between groups were analyzed to evaluate
immunological differences. Kruskal- Wallis analysis of
variance was performed for each variable; Comparisons
among the different groups were made using a two-tailed
Mann- Whitney test performed for independent samples.
Data analysis was performed using the MEDCALC
statistical package (MedCalc Software bvba, Mariakerke
Belgium).
RESULTS
Anti-inflammatory cytokines: MBP-stimulated
CD4+ T cells
PBMC from all patients and controls were
stimulated in vitro with MBP peptides or with
non-antigenic peptides. Cytofluorimetric analyses
were used to detect the percentage of CD4+T
lymphocytes producing different cytokines. As
expected, cytokine expression was not observed in
cell cultures incubated with non-antigenic MBP-
peptides. In contrast with these results, MBP-
stimulated IL-25- expressing CD4+ T lymphocytes
were augmented in RR and BEMS compared to
PP, SPMS and HC (p<O.OO I for RR and p<O.05 for
BEMS). Because IL-25 modulates IL-13 production,
this cytokine was examined next. Results showed
that IL-13-expressing CD4+ T lymphocytes were
significantly increased in BEMS compared to PPMS
and HC (p=O.OI5 in both cases) and decreased in
PP compared to SP (p=O.O 16) (Fig. I). Finally, IL4-
expressing CD4+ T cells were comparable in all
groups of individuals (data not shown).
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Fig. 1. Anti-inflammatory cytokines: CD4+ T lymphocytes. IL-25- and IL-13- expressing CD4+ T cells in unstimulated
conditions (A and C) or upon stimulation with a panel ofMB? peptides (B, D). Representative results obtained in multiple
sclerosis (MS) patients affected by primary progressive (PP), secondary progressive (SP), relapsing-remitting (RR), or
benign (BE) disease and in an age-and-sex-matched healthy control (HC). In the upper right corner the percentage
ofCD4+lLJ3+ or CD4+IL25+ is shown. Summary results of MBP-stimulated-anti-injlammatory cytokines-producing
CD4+T lymphocytes are presented in the bar graphs. The boxes stretch from the 25th to the 75th percentile; the lines
across the boxes indicate the median values; the lines stretching from the boxes indicate extreme values. Outside values
are displayed as separate points. Dots represent all data. Statistical significance is shown.
T lymphocytes expressing transcription factors
associated with Th2 differentiation
Transcription factors (TF) involved in Th-2
differentiation were analyzed next in MBP-stimulated
cells. Both NFATc-l- and GATA3- expressing CD4+
T lymphocytes were augmented in BEMS compared
to all other patients (p<O.05) and to HC (NFATcl:
p<O.05; GATA-3: p<O.O I); GATA-3-expressing cells
alone were increased in RRMS (p<O.05 vs PPMS,
SPMS, and p<O.OI vs HC) (Fig. 2). Notably, both
these TF are positively regulated by IL-25.
TH2 cells play an anti-inflammatory role, these data
thus suggest that in RR and BEMS a NFATc-l- and/or
GATA3-driven and IL-25-mediated mechanism that
hampers TH 17-associated inflammation is present;
this is not observed in PPMS and SPMS.
Anti-iriflammatory cytokines: MBP-stimulated
CD19+ cells
Whereas IL-IO expressing CD 19+ cells were
comparable in all groups of individuals, TGF~­
expressing B lymphocytes were significantly
increased in RRMS patients compared to SPMS
(p=O.OI)and HC (p=O.OOI) (Fig. 3).
MBP-stimulated pro-inflammatory cytokines in
CD4+ T lymphocytes
MBP-stimulated IL-17-expressing CD4+
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Fig. 2. Th-2 Transcription factors expressing CD4+ T lymphocytes. NFATc-l and GATA-3 expressing-CD4+ cells in
unstimulated conditions (A. C) or upon stimulation with a panel of MBP peptides (H. D) in MS patients with different
patterns ofdisease and healthy controls (HC). In the upper right corner the percentage ofCD4+ NFATc-l + or CD4+
GATA-3 + is shown. Summary results ofMBP-stimulated -TF-expressing- CD4+ T lymphocytes are presented in the hal'
graphs . The boxes stretch from the 25th to the 75th percentile; the lines across the boxes indicate the median values ; the
lines stretching from the boxes indicate extreme values. Outside values are displayed as separate points. Dots represent
al1data. Statistical significance is shown.
lymphocytes were significantly augmented (p<O.OO I
for all comparisons) in all groups of MS patients
compared to HC (Fig. 4).
IL-17 is produced by TH-17 together with other
cytokines including IL-21 and [L-22, these cytokines
were examined next. Whereas Ik-Zl-expressing
CD4+ T lymphocytes were similar in all patients and
controls, IL-22-expressing cells were significantly
augmented in RRMS, SPMS, and BEMS (p<O.05 for
all comparison), but not in PPMS patients, compared
to controls (Fig. 4). Notably, MBP-stimulated IFNy,
and IL-9- expressing CD4+ T cells were similar
between all groups of MS patients and when patients
were compared to controls (data not shown). These
results indicate that a TH 17-driven inflammatory
condition is present in all forms of MS.
T lymphocytes expressing transcription factors
associated with ThI and Th17 differentiation
T-bet- and RORC /yr-expressing T lymphocytes
were analyzed next; these TF are activated during the
differentiation of Th I and Th 17 cells, respectively.
Results showed that RORC/yr, involved in the
differentiation of naive cells toward the TH 17
lineage, was significantly increased in SP and RRMS
compared to HC (p=O.004 and p=O.OI, respectively)
(Fig. 5). CD8+ cells that expressed RORC/yr
were also augmented in all groups of MS patients
compared to controls (Fig. 5, lower right comer).
These cells were recently shown to produce [L-17
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Fig. 3. Anti-inflammatory cytokines: CD19+ cells. TGFfJ- expressing CD19+ cells in unstimulated conditions (A) or
upon stimulation with a panel ofMBP peptides (B): in MS patients with different patterns ofdisease and healthy controls
(HC). In the upper right corner the percentage ofCD19+TGFfJ+ cells is shown. Summary results obtained when MBP-
stimulated CD19+IL-lO-expressing cells were measured are presented in a separate panel. The boxes stretch from the
25th to the 75th percentile; the lines across the boxes indicate the median values; the lines stretching from the boxes
indicate extreme values. Outside values are displayed as separate points. Dots represent all data. Statistical significance
is shown.
and were suggested to playa role in the pathogenesis
of MS.
Finally, T-bet-expressing cells (T-bet is the TH 1-
associated TF) were comparable in all the groups
tested (data not shown).
Pro-inflammatory cytokines: CD14+ cells in MBP
-stimulated PBMC
Multiple cell types mediate immune responses; to
mimic as closely as possible the in vivo situation we
examined cytokine-expressing CD 14+ monocyte/
macrophages cells in MBP-peptides-stimulated
cultures of whole peripheral blood mononuclear
cells. Results indicated that IL-6- expressing CD14+
cells were significantly augmented in PP, SP, RR and
BEMS patients compared to HC (p=O.002, p=O.002,
p=O.04 and p=O.OOI respectively). Notably, IL-6-
expressing CD 14+ cells were increased in PP and
BEMS compared to SP as well (p=O.OO 1and p=O.003
respectively) and, finally, in BEMS compared to
RRMS (p=O.04) (Fig. 6). In contrast, IL-12 and IL-
23-producing CD 14+ cell were similar amongst all
among groups analyzed (data not shown).
MBP-stimulated cytokine production by PBMC
Non-immunogenic peptides- or MBP-stimulated
IL-17a, IL-6, IFN-y, IL-lO, IL-13, IL-12p70, IL-21,
IL-22, TGF-~, and IL-9 production was measured
next by ELISA. Results confirmed that stimulation of
cells with non-immunogenic peptides does not result
in the production of any cytokine. In contrast, data
obtained in MBP-stimulated cell cultures showed
that quantification of cytokines overall reflects
the pattern seen when intracellular cytokines were
measured by FACS. Therefore, IL-17, IL-6, and
TGF-~ were increased in all forms ofMS (p<O.OOI
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vs HC); the highest concentration ofTGF-~was seen
in RRMS; IL-22 was slightly increased in RRMS,
SPMS, and BEMS; and the production of IFN-y,
IL-IO IL-12p70, IL-21, and IL-9 was similar in all
analyzed groups. These results are shown in Fig. 7.
Unfortunately, neither IL-13 nor IL-25 production
could be measured because reagents for these
cytokines are either not sensitive enough or currently
not available.
DISCUSSION
To better define MBP-specific-TH cells in the
diverse clinical forms ofMS we analyzed such subsets
in patients affected by different forms ofdisease. Data
herein indicate that TH 17 lymphocytes dominate
MBP-specific immune response in all clinical forms
of MS. TH17 cells nevertheless produce a number of
cytokines, and different "functional TH 17 subsets"
were observed to prevail in patients affected by
phenotypically-diverse forms of MS. Thus, IL-
17-, IL-22-, or RORC/y[ - expressing cells were
increased in SP and RRMS patients, whereas cells
expressing IL-17 were augmented in PPMS and in
BEMS patients and IL-22 in BEMS compared to
He.
RORClyt is expressed by TH lymphocytes
that differentiate into TH 17 cells. Interestingly,
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results showed the presence of a sizable fraction
of RORCly. positive cells within the CD4-ICD8+
T lymphocyte population. CD8+ T lymphocytes
include a subpopulation of cells that express
RORCly. and produce lL-17. These cells, Tc17,
are characterized by a reduced cytotoxic function
along with low levels expression of the classical
CTL markers (Tbet, Granzyme Band IFN-y) (24),
and are suspected to be involved in the pathogenesis
of MS (18). This is based on the observations that
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a significant up-regulation of natural killer receptor
protein la/CD 161 as well as increased numbers of
CD 161high CD8 T cells is seen in the peripheral
blood of MS patients (25), and CD8+ T cells , and
in particular CD8+ CD 161+ cells can express IL-
22 and play an important role in the pathogenesis
of autoimmunity (26). As all circulating Tc17 cells
are contained within the CD 161high subset, it is
tempting to speculate that Tc do play a pathogenic
role in MS (27) possibly together with other cells,
including neutrophils (28).
IL-6-expressing monocyte/macrophages (MM)
were significantly augmented as well in all patients.
These data confirm that MBP-stimulated- IL-6
produc ing-CD 14+ monoc yte are increased in MS
patients (5) and indicate that an inflammatory
situation characterizes even those all clinical
phenotypes of MS (BE and RR during periods of
disease remission) in which disease activity is not
explicit. Notably, both cell belonging to adaptive and
innate immune systems over expre ssed inflammatory
cytokines in MS, reinforc ing the idea that this disease
is associated with inflammation and confirm ing
recent data indicating that MBP-specific Th-I , Th-2
and Th-I 7 responses correlat e with disease activity
(29).
Whereas TH I7 cells were comparable in
all clinical settings, the activation of GATA3-,
NFATc-1 - IL-13- and IL-25-expressing TH2 cells
was observed in RRMS and BEMS patients alone.
These results suggest that control over disease is not
associated with a lack of inflammation but, rather,
to the triggering on anti- inflammatory, TH2-driven
immune mechanisms. Such mechanisms prevail in
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RR- and BEMS patients, and are possibly responsible
for the dampening of disease.
TH2 cells secrete a number of cytokines. Among
these cytokines IL-25 and IL-13 play an important
role in controlling TH 17 activation: the action of
IL-25 is of particular interest as this cytokine down-
regulates TH 17 cells both directly and secondarily
to its ability to increase 1L-13 production. IL-25
also up-regulates NFATc-1, in tum increasing IL-4
production and enhancing GATA-3 expression and
Th2 differentiation(9). Because this cytokine was
augmented in RR and BEMS it is reasonable to
infer that it could be responsible for disease control.
Notably, NFATc-1-expressing cells were increased in
BEMS alone, suggesting the presence of a stronger
IL-25-mediated control mechanism on disease
progression in these patients. TGF~-expressing
B lymphocytes were also augmented in RRMS;
these cells are suggested to functionally be Breg
cells i.e. lymphocytes endowed with the ability to
down-regulate immune responses (30). A number of
reports dwell on the role ofTreg lymphocytes in MS;
to our knowledge this is the first time that Breg are
suggested to also play a role in controlling disease
relapses in MS patients.
Cytokines produced by MBP-stimulated
PBMC were also measured; results confirmed that
inflammatory cytokines belonging to both innate (IL-
6) and acquired (IL-17) immunity are significantly
increased in all forms of MS compared to controls.
Results also showed that TGF~ is overproduced
in MS patients in a possible attempt to quench
neuroinflammation: an attempt that is successful in
RRand BEMS.
The pathogenic role played by TH 17 cells in MS
is likely secondary to the ability of IL-17 and IL-22
to bind specific receptors on the endothelial cells on
the BBB (20, 31); this results in the disruption of the
tight junctions that characterize this barrier, allowing
the penetration ofmonocytes and lymphocytes within
the CNS. In the presence of an inflammatory milieu
this facilitates neuronal death and the perpetuation
of CNS inflammation through CD4+ T lymphocyte
recruitment (20). The observation that IL-22 was
increased in SP but not in PPMS could explain the
higher-grade inflammation and active demyelination
that is seen in brain plaques of SPMS (32). Notably,
BBB-endothelial cells also favor the differentiation
of peripheral blood-derived CD 14+ monocytes into
functional myeloid dendritic cells (mOe) that can
support the proliferation and expansion of TH 17
cells (33), processes that require also the presence
of IL-6. Results showing that IL-6-expressing
CD 14+ cells were increased in MS could explain
the massive increases of TH 17 lymphocytes seen in
these patients.
A particular finding was that MBP-stimulated
IL-6 production was greatly augmented in a subset
of BEMS patients; no concurrent infections and
no other inflammatory conditions were present in
these individuals. One explanation stems from the
suggestion that inflammatory responses might have
beneficial effects in demyelinating disease. Thus,
the immune process in demyelinating disease could
have a beneficial permissive role in creating the
conditions for remyelination and repair to take place
(34).
No differences were seen in IL-9-expressing (TH9)
cells, suggesting that this TH functional phenotype
(13) might not playa role in the pathogenesis of MS.
Nor were any differences observed either in TH 1-
associated TF or in TH 1 cytokines-secreting CD4+
or CD 14 cells. These results are in contrast with
previous data (35). The higher percentage of IL-
l Oeexpressing compared to that of IFNy-generating
cells could justify this observation that, nevertheless,
needs to be further explored.
Data herein suggest that the upregulation of TH2
cells seen in quiescent MS is a successful attempt
by the immune response to reduce TH I7 activation,
its failure allowing neuroinflammation to develop.
The acquisition of disease quiescence in MS might
therefore not be a passive (reduction of TH 17
cells), but rather an active (activation of TH2 cells)
immune phenomenon. Notably, IL-25 ameliorates
autoimmune diabetes (36) and exerts a protective
effect in EAE (7) that is mediated by the reduction of
TH 17 cells in an IL-13/IL25- and/or a NFATc-1- and
GATA-3- dependent manner (6-9). These data could
warrant the investigation of a possible utilization of
IL-13 and IL-25 as therapeutic agents.
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